{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.528","upperLimit":"15.510","value":"14.019"},{"groupId":"OG001","lowerLimit":"11.798","upperLimit":"14.780","value":"13.289"},{"groupId":"OG002","lowerLimit":"6.340","upperLimit":"10.147","value":"8.243"},{"groupId":"OG003","lowerLimit":"7.288","upperLimit":"11.426","value":"9.357"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"33"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.503","upperLimit":"13.434","value":"11.968"},{"groupId":"OG001","lowerLimit":"9.685","upperLimit":"12.616","value":"11.151"},{"groupId":"OG002","lowerLimit":"6.226","upperLimit":"10.079","value":"8.153"},{"groupId":"OG003","lowerLimit":"6.258","upperLimit":"9.816","value":"8.037"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"34"}],"units":"Participants"}],"title":"Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"34"}],"units":"Participants"}],"description":"Summarized data for Cycle 1 and Cycle 2 was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with MDS or CMML received decitabine 20 mg/m\\^2 IV injection, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days).","id":"OG000","title":"MDS or CMML: IV Decitabine"},{"description":"Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, given by mouth, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days). From cycle 3, participants received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG001","title":"MDS or CMML: ASTX727"},{"description":"Participants with AML received decitabine 20 mg/m\\^2 IV injection, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days).","id":"OG002","title":"AML: IV Decitabine"},{"description":"Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, given by mouth, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days). From cycle 3, participants received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG003","title":"AML: ASTX727"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Pharmacodynamic (PD) LINE-1 Analysis Set included participants who received any amount of study treatment and have LINE-1 methylation data at baseline (Day 1) of Cycle 1 or 2 and on either Day 8 or Day 15 of the respective cycle. 'Overall number of participants analyzed' signifies those who were evaluable for this outcome measure. 'Number analyzed' signifies those participants who were evaluable for this outcome measure at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycles 1 and 2 (as Baseline), and Days 8, 15 and 22 of Cycles 1 and 2 (each cycle= 28 days)","title":"Maximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation","type":"SECONDARY","unitOfMeasure":"percentage of demethylation"}